CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
EN
Home / Sanofi (SNY) / amlitelimab
Forward catalyst · SNY

amlitelimab

Sponsor Sanofi · listed as SNY

READOUT Phase 3 Confidence: medium Source: clinicaltrials

amlitelimab is a clinical-stage drug asset sponsored by Sanofi, listed as SNY. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Sep 30, 2027 (day precision, medium confidence), tied to trial NCT06241118. The asset is in Phase 3 and currently active not recruiting, studied in Dermatitis Atopic. It appears across 3 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2027-09-30
As disclosedSep 30, 2027
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT06241118
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorSanofi
Listed asSNY
Condition(s)Dermatitis Atopic
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,221 forward catalysts, 955 of them linked to 124 listed sponsors.

Get the full dataset — $499 →   More SNY catalysts

Related catalysts and sponsor